Positive efficacy and durability data reinforce anzu-cel's potential in melanoma; investors should watch for SUPRAME Phase 3 enrollment progress and any competitive developments. The 1H 2027 BLA submission timeline provides a medium-term catalyst.
IMTX drugs
IMTX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 1 $11.14entry
- T+1 · 6mo ago −9.87%α −10.02% · $10.04
- T+5 · 5mo ago −12.12%α −9.37% · $9.79
- T+20 · 5mo ago −9.07%α −7.77% · $10.13
- T+60 · 3mo ago −17.06%α −18.29% · $9.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immatics reports extended Phase 1b data for anzu-cel (PRAME TCR T-cell therapy) in metastatic melanoma at ASCO 2026, showing 56% confirmed ORR, 14.6-month median DOR, 6.1-month median PFS, and 16.2-month median OS with manageable safety. The Phase 3 SUPRAME trial remains on track with BLA submission expected in 1H 2027.
Key Facts
- 56% confirmed objective response rate (cORR) in heavily pretreated metastatic melanoma (N=33)
- Median duration of response (mDOR) of 14.6 months; median PFS 6.1 months; median OS 16.2 months
- Phase 3 SUPRAME trial advancing; BLA submission targeted for 1H 2027
- Predictable and manageable safety profile with mostly Grade 1-2 CRS and infrequent ICANS
- Anzu-cel demonstrated systemic anti-tumor activity across multiple metastatic sites including liver, lung, and brain
Financial Impact
Positive clinical data supports the potential of anzu-cel as a first-in-class PRAME-directed cell therapy, though no financial figures provided.
Risk Factors
- Data is from Phase 1b; Phase 3 may not replicate results
- Competitive landscape includes approved checkpoint inhibitors and other cell therapies
- Regulatory approval and commercial launch are uncertain and costly
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304266 |
Track record
23 reports on IMTX
8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 5/10 No price data
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
- Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
- Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
- Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
- Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers